Loading stock data…
$2.46-0.13 (-5.19%)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.46 with a market capitalization of $244M. Wall Street consensus targets $11.60 (5 analysts), implying a +370.6% move over the next 12 months. The stock is currently near its 52-week low of $2.44, remaining 36.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.81M↑ | $2.71M↑ | $2.57M↑ | $1.76M↓ | $1.97M |
| Gross Profit | $7.19M↑ | $2.11M↓ | $2.20M↑ | $1.41M↓ | $1.65M |
| Operating Income | -$16.39M↑ | -$20.31M↑ | -$23.70M↑ | -$27.51M↓ | -$26.23M |
| Net Income | -$16.16M↑ | -$20.24M↑ | -$23.93M↑ | -$29.82M↓ | -$25.74M |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...